Used in cancer immunotherapy research to block the TIGIT pathway, enhancing T cell and NK cell activity against tumors. Supports development of treatments for solid tumors and hematologic malignancies by promoting anti-tumor immune responses. Employed as a reference standard in preclinical studies to evaluate efficacy, binding affinity, and mechanism of action of experimental TIGIT inhibitors. Facilitates biomarker identification and assay validation in immuno-oncology drug development.